Creative Planning
RXRX icon

Creative Planning’s Recursion Pharmaceuticals RXRX Stock Holding History

Creative Planning’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,000
Closed -$598 – 4073
2025
Q3 		$598 Buy
+2,000
New +$10.5K ﹤0.01% 3899

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Creative Planning's RXRX Position: Q1 2026 in Review

Creative Planning increased its Recursion Pharmaceuticals (RXRX) stake by 90% in Q1 2026, buying an estimated $173K and bringing the position to 94,208 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #3456.

Creative Planning first reported a position in RXRX in Q3 2023 and has held it in 7 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Creative Planning held 94,208 shares of Recursion Pharmaceuticals worth $289K as of Q1 2026.
  • Creative Planning bought 44,673 Recursion Pharmaceuticals shares in Q1 2026, an estimated $173K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #3456 holding.
  • Creative Planning first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 7 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.